Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    " June 02, 2010":" July 02, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 02, 2010":" July 02, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Uganda
Condition: HIV Infection
Interventions: Behavioral: Invitation letter for male spouse;   Behavioral: Information letter
2 Unknown  Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults
Condition: HIV Infection
Intervention: Biological: Adjuvanted vaccine against H1N1 influenza virus (GSK)
3 Unknown  Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
Condition: HIV Positive
Intervention:
4 Completed Pharmacokinetics of Low Dose Raltegravir
Condition: HIV Infections
Intervention: Drug: raltegravir
5 Unknown  Study of Cell Phone SMS Messages for Prevention of Maternal to Child Transmission of HIV
Condition: HIV Infections
Intervention: Behavioral: cell phone sms text messaging
6 Completed RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice
Condition: HIV Positive
Intervention:
7 Completed Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies
Condition: HIV Infection
Interventions: Behavioral: Linkage-to-Care Component: Financial Incentive (FI);   Behavioral: Linkage-to-Care Component: Standard of Care (SOC);   Behavioral: Viral Suppression Component: FI;   Behavioral: Viral Suppression Component: SOC;   Behavioral: Prevention for Positives Component: Counseling and SOC;   Behavioral: Prevention for Positives Component: SOC
8 Completed
Has Results
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Condition: HIV Infections
Interventions: Biological: TUTI-16 (0.2mg);   Biological: TUTI-16 (1.0 mg)
9 Completed Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)
Condition: HIV Infections
Intervention: Drug: ATV/r
10 Completed
Has Results
Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men
Conditions: HIV Seroconversion;   Stimulant Abuse
Intervention: Drug: Truvada
11 Completed A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring
Condition: HIV Infections
Interventions: Drug: dapivirine;   Drug: placebo
12 Completed Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)
Condition: HIV Infections
Intervention:
13 Completed Tenofovir Gel in Pregnancy and Lactation
Condition: HIV Infections
Interventions: Drug: Tenofovir 1% gel;   Other: Placebo gel
14 Completed Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda
Condition: HIV-infection/Aids
Intervention:
15 Completed A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings
Conditions: Male Circumcision;   HIV Prevention;   HIV Infections
Intervention: Device: The PrePex a novel device for adult male circumcision
16 Completed
Has Results
Treatment Options for Protease Inhibitor-exposed Children
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: Efavirenz (EFV);   Drug: Lopinavir/ritonavir (LPV/r);   Drug: Stavudine (D4T);   Drug: Abacavir (ABC)
17 Completed Metabolic and Psychological Changes Associated With Menopause Among Women With HIV
Conditions: HIV Infections;   Menopause
Intervention:
18 Completed
Has Results
Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)
Conditions: Tuberculosis;   HIV Infections
Interventions: Biological: MVA85A/AERAS-485;   Biological: Placebo
19 Active, not recruiting Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation
Conditions: Renal Function;   HIV Infection
Intervention: Other: Tc99mDTPA renal clearance
20 Completed Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: LPV/r

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.